Public Policy Letters, Statements, Legal Briefs, & Other Responses
-
ACMG Letter to Congress Concerning the FDA Technical Assistance for the Diagnostic Accuracy and Innovation Act (DAIA)
-
Group Sign-on Letter to Congress Concerning the Diagnostic Accuracy and Innovation Act (DAIA)
-
Group Sign-on Letter to Congress Opposing the Preserving Employee Wellness Programs Act (HR 1313)
-
ACMG/AMP/IDSA Joint Congressional Briefing on LDTs
-
ACMG-AMP Joint Webinar on Regulatory Oversite of LDTs (recording)
-
ACMG-AMP Joint Webinar on Regulatory Oversite of LDTs (slides)
-
ACMG Comments to EEOC Concerning Proposed Rule Related to the Genetic Information Nondiscrimination Act (GINA)
-
ACMG Comments to OHRP Concerning Proposed Revisions to the Common Rule
-
ACMG Testimony in Support of the Accurate Education for Prenatal Screenings Act (HR 3441)
-
ACMG Response to FDA’s Proposed Regulatory Framework for LDTs